SpringerLink
Log in

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

  • Case Report - Complication
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Little is known about the efficacy and safety of durvalumab plus carboplatin-etoposide treatment in patients with extensive-disease (ED) small-cell lung cancer (SCLC) on hemodialysis. Here, we present a case of a 67-year-old man with pleuroperitoneal communication on continuous ambulatory peritoneal dialysis who was diagnosed with ED-SCLC based on a cytological analysis of the peritoneal fluid. He was switched from peritoneal dialysis to hemodialysis and received durvalumab (1500 mg/body on day 1) plus carboplatin (area under the concentration–time curve = 5, 125 mg on day 1) and etoposide (50 mg/m2 on days 1 and 3) as first-line therapy. During the first cycle, grade 2 anemia, grade 3 neutropenia, and grade 3 upper gastrointestinal bleeding occurred; therefore, durvalumab and reduced doses of carboplatin and etoposide were administered. No other severe adverse events occurred, and a partial response was observed after four cycles. Our findings indicate that durvalumab plus carboplatin-etoposide treatment is safe and effective even in patients on hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

All data included in this report are available upon reasonable request from the corresponding author.

References

  1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

    Article  PubMed  Google Scholar 

  2. Oronsky B, Reid TR, Oronsky A, Carter CA (2017) What’s new in SCLC? A review. Neoplasia 19:842–847. https://doi.org/10.1016/j.neo.2017.07.007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wang S, Tang J, Sun T et al (2017) Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep 7:1339. https://doi.org/10.1038/s41598-017-01571-0

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  4. Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121:664–672. https://doi.org/10.1002/cncr.29098

    Article  CAS  PubMed  Google Scholar 

  5. Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929–1939. https://doi.org/10.1016/s0140-6736(19)32222-6

    Article  CAS  PubMed  Google Scholar 

  6. Cheun H, Kim M, Lee H et al (2019) Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drug 37:579–583. https://doi.org/10.1007/s10637-018-0673-y

    Article  Google Scholar 

  7. Thurlow JS, Joshi M, Yan G et al (2021) Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol 52:98–107. https://doi.org/10.1159/000514550

    Article  PubMed  Google Scholar 

  8. Na SY, Sung JY, Chang JH et al (2011) Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 33:121–130. https://doi.org/10.1159/000323740

    Article  PubMed  Google Scholar 

  9. Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99. https://doi.org/10.1016/s0140-6736(99)06154-1

    Article  CAS  PubMed  Google Scholar 

  10. Janus N, Thariat J, Boulanger H et al (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21:1395–1403. https://doi.org/10.1093/annonc/mdp598

    Article  CAS  PubMed  Google Scholar 

  11. Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493–507. https://doi.org/10.2165/11531280-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  12. Centanni M, Moes DJAR, Trocóniz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58:835–857. https://doi.org/10.1007/s40262-019-00748-2

    Article  PubMed  PubMed Central  Google Scholar 

  13. Imaji M, Fujimoto D, Kato M et al (2021) Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature. Respirol Case Reports 9:e00741. https://doi.org/10.1002/rcr2.741

    Article  Google Scholar 

  14. Ishizuka S, Sakata S, Yoshida C et al (2018) Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression. Respir Investig 56:361–364. https://doi.org/10.1016/j.resinv.2018.03.005

    Article  PubMed  Google Scholar 

  15. Osa A, Uenami T, Naito Y et al (2019) Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. Thorac Cancer 10:2183–2187. https://doi.org/10.1111/1759-7714.13197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Strohbehn IA, Lee M, Seethapathy H et al (2020) Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series. Am J Kidney Dis 76:299–302. https://doi.org/10.1053/j.ajkd.2020.02.451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Funakoshi T, Horimatsu T, Nakamura M et al (2018) Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open 3:e000301. https://doi.org/10.1136/esmoopen-2017-000301

    Article  PubMed  PubMed Central  Google Scholar 

  18. Wang J, Dasari S, Elantably D et al (2022) Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data. Acta Oncol 61:1157–1161. https://doi.org/10.1080/0284186x.2022.2127121

    Article  CAS  PubMed  Google Scholar 

  19. Yanagita M, Muto S, Nishiyama H et al (2023) Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. https://doi.org/10.1007/s10157-023-02415-0

    Article  PubMed  PubMed Central  Google Scholar 

  20. Leung TV, Hughes ME, Cambareri CG et al (2018) Systemic treatments for lung cancer patients receiving hemodialysis. J Adv Pract Oncol 9:614–629

    PubMed  PubMed Central  Google Scholar 

  21. Krens SD, Lassche G, Jansman FGA et al (2019) Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 20:e200–e207. https://doi.org/10.1016/s1470-2045(19)30145-7

    Article  CAS  PubMed  Google Scholar 

  22. Takezawa K, Okamoto I, Fukuoka M, Nakagawa K (2008) Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J Thorac Oncol 3:1073–1075. https://doi.org/10.1097/jto.0b013e318183af89

    Article  PubMed  Google Scholar 

  23. Belani CP, Kearns CM, Zuhowski EG et al (1999) Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non–small-cell lung cancer. J Clin Oncol 17:676–676. https://doi.org/10.1200/jco.1999.17.2.676

    Article  CAS  PubMed  Google Scholar 

  24. Kim YH, Mio T, Hamamoto Y, Mishima M (2010) Successful treatment with carboplatin and etoposide in a small-cell lung cancer patient undergoing hemodialysis. Respir Med Cme 3:68–70. https://doi.org/10.1016/j.rmedc.2009.05.006

    Article  Google Scholar 

  25. Inoue A, Saijo Y, Kikuchi T et al (2004) Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 15:51–54. https://doi.org/10.1093/annonc/mdh008

    Article  CAS  PubMed  Google Scholar 

  26. Watanabe M, Aoki Y, Tomita M et al (2002) Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 84:335–338. https://doi.org/10.1006/gyno.2001.6527

    Article  PubMed  Google Scholar 

  27. Chatelut E, Rostaing L, Gualano V et al (1994) Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 66:157–161. https://doi.org/10.1159/000187794

    Article  CAS  PubMed  Google Scholar 

  28. Oguri T, Shimokata T, Inada M et al (2010) Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol 66:813–817. https://doi.org/10.1007/s00280-010-1366-1

    Article  CAS  PubMed  Google Scholar 

  29. Oguri T, Shimokata T, Ito I et al (2015) Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol 76:53–59. https://doi.org/10.1007/s00280-015-2769-9

    Article  CAS  PubMed  Google Scholar 

  30. Shimokata T, Ando Y, Yasuda Y et al (2010) Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci 101:2601–2605. https://doi.org/10.1111/j.1349-7006.2010.01729.x

    Article  CAS  PubMed  Google Scholar 

  31. Hatta T, Hase T, Hara T et al (2023) Adjustment of creatinine clearance for carboplatin dosing in Calvert’s formula and clinical efficacy for lung cancer. Cancer Med 12:15955–15969. https://doi.org/10.1002/cam4.6235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Funding

This work was not supported by funding, grants, or other sources.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Futoshi Ushijima, Tetsunari Hase, Yuki Yamashita, Tomonori Sato, Tomoya Baba, Shohei Watanabe, Keisuke Futamura & Makoto Ishii

  2. Department of Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Hangsoo Kim & Masashi Mizuno

  3. Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan

    Tomoya Shimokata, Chiaki Kondo & Yuichi Ando

Authors
  1. Futoshi Ushijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsunari Hase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hangsoo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoya Shimokata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiaki Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomonori Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomoya Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shohei Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keisuke Futamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuichi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masashi Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Makoto Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the conception and design of the study. FU and TH wrote the first draft of the manuscript.

Corresponding author

Correspondence to Tetsunari Hase.

Ethics declarations

Conflict of interest

T.H. received personal fees and research funding from AstraZeneca KK outside the submitted work. Y.A. received personal fees from Chugai Pharmaceutical Co., Ltd. and Bayer Holding Ltd., and research funding from Chugai Pharmaceutical Co., Ltd., Bayer Holding Ltd., BeiGene Inc., and Geo Holdings Co., Ltd. M.I. received personal fees from AstraZeneca KK outside the submitted work. All remaining authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Given that this is a case report without the inclusion of any identifying information, formal consent was not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ushijima, F., Hase, T., Yamashita, Y. et al. Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review. Int Canc Conf J 13, 88–92 (2024). https://doi.org/10.1007/s13691-023-00640-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-023-00640-8

Keywords

Search

Navigation